Newsletter
| Promoter: | Penny Stock Money Train | Paying Party: | Creme Dellatex |
| Stocks covered: | Compensation: | Avg $ Volume for Period: |
| XYTS | $20000 | 3577 |
| Max Profit: 29.41 % | Gain at close: 23.53 % | |
| *We think that this promoter is a part of a group of promoters. | ||
Today I would like to focus my attention on an “Undiscovered” Biotech company that has made leaps and bounds in the areas of treating certain cancers…
… and the Company has not yet released news about the amount of jaw-dropping success to the public in eliminating cancer cells to the point that they are undetectable.
Moreover, “the company has moved quickly to position itself to start treating patients in the United States and other areas to be announced.”
This company that I found could easily be one of those MAJOR WINNERS that we sometimes hear about with bio-techs that make explosive moves to the upside, so hold on to your seats because this “unknown” company is in a positioned to explode.
My New “Undiscovered” Cancer Treatment Company is…
XYTS (XYTOS, Inc.) introduces Next Generation Advanced Bio-Medical Technologies in the following areas:
#1. Cancer Treatment
#2. Stem Cell Therapy
For the past several years XYTS has been “secretly” focused on its remarkable results in the fight against cancer until the approvals were in place to treat diseases and the Doctors ready to start treating patients in the U.S. to the mainstream public.
The company has treated prostate and breast cancers, but also melanoma, ovarian, squamous cell, mesothelioma, adrenal, colon, endometrial and unknown (primary not found).
Below are the major points that traders could want to know:
- XYTS’ technology is NON-INVASTIVE
-
Administration to patients causes negligible side effects during treatment and have no evidence of any longer term side effects.
-
All early stage patients were treated with apparent success, and XYTS was able to prove success with breast and skin cancer along with a selection of other cancers.
XYTS is working at the forefront of the "Science of Medicine" and positioning itself as a Global Leader in the introduction of Advanced Cancer Treatment.
According to Tim Cook, Chairman and CEO of XYTS, Inc. commented, “We now have the necessary foundation in place to insure that XYTOS becomes a Global Leader in Advanced Medicine.”
XYTS’s First-to-Market Competitive Advantage
XYTS received a very unique and rare medical approval in U.S. to treat patients with their proprietary bio-medical techniques which are non-invasive for breast, skin and prostate cancers.
XyChloro is a next generation photosensitizer that demonstrates XYTS’s increasing commitment to eliminate cancer and offer its patients a better quality of life.
Note that this demonstrates a potential HUGE breakout in the fight against cancer!
Moreover, XYTS's cancer treatment is NON-INVASIVE. The agent concentrates in tumor cells because the tumor cells have a lactic acid metabolism and a negative charge.
Based upon my research and discussion with the CEO, it is my understanding that XYTS has received special permission to treat Stage 1 and 2 patients in the United States without FDA Approval partly due to do the fact that it is a non-invasive technique. Stage 1 and 2 is cancer is the type that has not metastasized yet (haven’t spread yet). Stage 3 is where cancer begins to spread and Stage to 4 is where it has spread further like into the bone.
In the most simple way to explain how the treatment works, patients place the substance under the tongue, then are treated with light and sound technologies.
---------------------------Positive Technical Growth
For the past few weeks XYTS has been trading at consistent levels, thus forming a strong level of support.
I believe shares are currently positioned to experience this type of upward trend as the MACD has been signaling upwards. This is a strong indicator of increased momentum!